RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was USD 0.038381 million compared to USD 0.038381 million a year ago. Net loss was USD 0.970041 million compared to USD 0.718325 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.